More Business Wire

View Older Stories View Newer Stories

Oct 23, 2023 06:00AM reAlpha Announces Effectiveness of Registration Statement for Proposed Direct Listing of Its Common Stock on Nasdaq

Oct 23, 2023 06:00AM Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Oct 23, 2023 05:30AM HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

Oct 23, 2023 05:10AM Elavon Financial Services Receives UK Banking Authorisation

Oct 23, 2023 05:00AM Redwire Awarded Contract to Provide Onboard Computer for ESA’s Comet Interceptor Mission to Study Pristine Comet

Oct 23, 2023 05:00AM Plata Partners with Entersekt to Protect its Credit Card with 3-D Secure Payment Authentication

Oct 23, 2023 05:00AM Chevron Announces Agreement to Acquire Hess

Oct 23, 2023 04:47AM Business Park Sofia Elevates Peter Kunzov to General Counsel and Ekaterina Radeva to Head of Special Projects & ESG Initiatives

Oct 23, 2023 04:46AM Business Park Sofia Appoints Jordan Krastev as Chief Commercial Officer and Managing Director

Oct 23, 2023 04:46AM Business Park Sofia Appoints Konstantin Pavlov as Chief Financial Officer

Oct 23, 2023 04:00AM Amid Cost Of Living Crisis, UK Consumers Look To Shake Up How They Access And Use Credit

Oct 23, 2023 04:00AM LiveWire® Opens European Reservations for S2 Del Mar® and Confirms Pricing and Delivery Schedule

Oct 23, 2023 04:00AM Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

Oct 23, 2023 04:00AM RE: Aubit International (in official liquidation) (the “Company”)

Oct 23, 2023 03:45AM First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Oct 23, 2023 03:15AM Tineco Floor One S7 Steam, the 3-in-1 Smart Cordless Steam Floor Washer

Oct 23, 2023 03:15AM Tineco Presents the FLOOR ONE S7 Steam - the 3-in-1 Cleaning Device for the Household

Oct 23, 2023 03:13AM United States: TotalEnergies Joins Forces With Corio and Rise to Develop 3+ GW Wind Project Offshore New York & New Jersey

Oct 23, 2023 03:05AM Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

Oct 23, 2023 03:00AM Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers

Oct 23, 2023 03:00AM ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo

Oct 23, 2023 03:00AM Mind Your Money: 5 Tips From Pocket Money Card nimbl to Spot and Stop Online Fraud

Oct 23, 2023 03:00AM CYBERIA Announces first Akamai DDoS Scrubbing Center in Saudi Arabia

Oct 23, 2023 02:50AM National Football League Teams Up with SES for Game Content Distribution

Oct 23, 2023 02:30AM Tineco Unveils the Floor One S7 Steam, Its New Intelligent Vacuum Cleaner to Sanitize All the Rooms in Your Home

Oct 23, 2023 02:21AM Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

Oct 23, 2023 02:15AM Alphawave Semi Announces Appointment of Rahul Mathur as Chief Financial Officer

Oct 23, 2023 02:15AM Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2023

Oct 23, 2023 02:15AM Nidec Announces Differences between Projected and Actual Financial Results for First-Half FY2023

Oct 23, 2023 02:00AM ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Oct 23, 2023 02:00AM MaxLinear’s URX Open Source Platform and prpl Foundation’s prplOS Drive Innovation in Home Connectivity at prpl Summit 2023

Oct 23, 2023 02:00AM EH Group tests HTPEM Fuel Cell to decarbonise aviation

Oct 23, 2023 02:00AM Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’

Oct 23, 2023 01:00AM CARMAT Presented Its Progress on the EFICAS Clinical Study at the 36th Journées de La Pitié in Paris

Oct 23, 2023 01:00AM SHL Telemedicine Announces Advancements in its Direct-to-Consumer Strategy in the US

Oct 23, 2023 01:00AM Azelis Reinforces Its Footprint in the EMEA Flavors & Fragrances Market With the Acquisition of BLH

Oct 23, 2023 01:00AM APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations

Oct 22, 2023 09:10PM Teen Cosmetic Company, Prom Queen, takes Center Stage on Macys.com

Oct 22, 2023 08:03PM Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters

Oct 22, 2023 07:30PM Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland

Oct 22, 2023 07:12PM Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Oct 22, 2023 06:00PM Marqeta Study: Even Satisfied Credit Cardholders Are Shopping For Their Next Card, Seeking Tailored Rewards and Embedded Finance Experiences

Oct 22, 2023 01:00PM Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

Oct 22, 2023 12:00PM Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Oct 22, 2023 10:30AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urot

Oct 22, 2023 10:30AM Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Lin

Oct 22, 2023 09:00AM Unit21 Launches Real-Time Monitoring to Fight Real-Time Fraud

Oct 22, 2023 07:00AM Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/I

Oct 22, 2023 04:15AM Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

Oct 22, 2023 02:30AM Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

View Newer Stories View Older Stories